Condition

Metastatic Pancreatic Adenocarcinoma clinical trials and research

• 12Clinical trials
• 11Countries

Newest Metastatic Pancreatic Adenocarcinoma clinical trials

All recruiting trials (12)

• AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer

  This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07619313

• Setidegrasib with mFOLFIRINOX or NALIRIFOX for KRAS G12D metastatic pancreatic cancer

  This trial tests whether adding setidegrasib to mFOLFIRINOX or NALIRIFOX helps people with metastatic pancreatic cancer who have a KRAS G12D mutation.

  Recruiting at 104 sites Phase 3 Astellas Pharma Inc · Gilbert, Arizona and 103 other locations · NCT07409272

• BMS-986340 with nivolumab plus gemcitabine and nab-paclitaxel for advanced or recurrent pancreatic adenocarcinoma

  This trial tests whether adding the antibody BMS-986340 to nivolumab together with gemcitabine and nab-paclitaxel helps people with metastatic or recurrent pancreatic adenocarcinoma.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT07226856

• TR-002 (Nadofaragene Firadenovec) given by IV for adults with advanced unresectable or metastatic solid tumors and refractory metastatic pancreatic adenocarcinoma

  This Phase 1 trial tests whether weekly intravenous TR-002 is safe and what dose is best for adults with advanced unresectable or metastatic solid tumors or refractory metastatic pancreatic cancer.

  Recruiting Phase 1 University of California, Davis · Sacramento, California · NCT07189195

• Comparing NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen for advanced pancreatic adenocarcinoma

  This compares NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen to see if it helps people with untreated locally advanced or metastatic pancreatic ductal adenocarcinoma live longer or have better tumor responses.

  Recruiting at 2 sites Phase 2 Medical University of South Carolina · Charleston, South Carolina and 1 other locations · NCT07076212

• Adding panitumumab to chemotherapy for unresectable or metastatic KRAS wild-type pancreatic cancer

  This trial will test whether giving the antibody panitumumab along with standard chemotherapy helps people with unresectable, locally advanced, or metastatic KRAS wild-type pancreatic cancer live longer.

  Recruiting at 272 sites Phase 3 SWOG Cancer Research Network · Anchorage, Alaska and 273 other locations · NCT06998940

• Combination treatment for metastatic pancreatic cancer using chemotherapy and a special device

  This study is testing a new treatment for metastatic pancreatic cancer that combines chemotherapy with a special device to see if it helps patients better than current options.

  Recruiting at 7 sites Phase 2 Barbara Ann Karmanos Cancer Institute · Clarkston, Michigan and 6 other locations · NCT06576115

• Telehealth coaching to improve life quality for pancreatic cancer survivors and their caregivers

  This study tests whether telehealth coaching can help improve the quality of life for people surviving pancreatic cancer and their caregivers.

  Recruiting City of Hope Medical Center · Arcadia, California and 21 other locations · NCT06524973

• Investigating a new drug combination for advanced pancreatic cancer

  This study is testing a new combination of three drugs to see if it helps people with advanced pancreatic cancer feel better and live longer.

  Recruiting at 2 sites Phase 1 Chang Gung Memorial Hospital · Chiayi City and 2 other locations · NCT06229496

• Testing a combination of two anti-cancer drugs for HER2-positive solid tumors

  This study is testing a combination of two cancer drugs to see if they can safely help people with advanced HER2-positive solid tumors.

  Recruiting at 15 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 17 other locations · NCT05372614

• iExosomes for metastatic pancreatic cancer with KRAS G12D mutation

  This trial will test if iExosomes — tiny vesicles made from mesenchymal stromal cells that carry KRAS G12D-targeting siRNA — can help people with metastatic pancreatic ductal adenocarcinoma who have the KRAS G12D mutation.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT03608631

• Comparing glufosfamide and 5-FU for advanced pancreatic cancer treatment

  This study is testing whether a new drug called glufosfamide can help people with advanced pancreatic cancer live longer compared to the standard treatment of 5-FU.

  Recruiting at 3 sites Phase 3 Eleison Pharmaceuticals LLC. · Whittier, California and 2 other locations · NCT01954992

Related topics

Quick answers

How many Metastatic Pancreatic Adenocarcinoma clinical trials are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in United States (11 trials), Taiwan (2 trials), Brazil (1 trial), China (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 4, Phase 2: 3, Phase 3: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →